Back to results

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

Primary Purpose

Diabetic Foot Ulcer

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

gentamicin-collagen sponge and levofloxacin

Levofloxacin only

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcer focused on measuring Diabetes, ulcers, ulcerations, infection

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Is a man or woman aged ≥ 18 and ≤ 80 years.
Has diabetes mellitus, according to the American Diabetes Association criteria.
Has a single infected skin ulcer below the knee, defined as "moderate" by the Infectious Disease Society of America (IDSA) Guidelines for whom, in the Investigator's opinion, intravenous (IV) or oral antimicrobial therapy is appropriate
Has had an x ray of the infected area within the 2 days immediately preceding or at Visit 1 (Baseline/Randomization) to document the presence or absence of osteomyelitis. Patients with osteomyelitis must receive appropriate surgical intervention to remove all necrotic and infected bone and otherwise meet enrollment criteria before being enrolled in the study.
Meets certain minimal laboratory criteria
Has an ankle brachial index (ABI) > or = 0.7 and ≤ 1.3. (Note: Patients with ABI < 0.7 or > 1.3 may be included if they have either a transcutaneous oxygen pressure or a toe pressure > or = 40 mm Hg on limb with ulcer.)
If female, is nonpregnant (negative pregnancy test results at the Baseline/Randomization Visit) and nonlactating.
If female, is either not of childbearing potential (defined as postmenopausal for ≥ 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing a medically acceptable methods of birth control and agrees to continue with the regimen throughout the study
Willing to return to the study facility for the Final Study Visit.
Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.

Exclusion Criteria:

Has a known history of hypersensitivity to gentamicin (or other systemic aminoglycosides) or levofloxacin or drugs in the same class, or any of the test article or reference product components.
Has a known hypersensitivity to bovine collagen.
Has any uncontrolled illnesses that, in the opinion of the Investigator, would interfere with interpreting the results of the study.
Has a target ulcer with a wound size > 10 × 10 cm.
Has gangrenous tissue of the affected limb that cannot be removed with a single debridement.
Has wound known to contain isolates resistant to levofloxacin.
Has a wound associated with prosthetic material or device.
Received any topical or systemic antimicrobial therapy within the 2 weeks prior to study entry (Visit 1 [Day 1]).
If severely immunocompromised, may be excluded at the discretion of the Investigator.
Has a history of alcohol or substance abuse in the past 12 months.
Has serum creatinine > 3 mg/dL, is undergoing dialysis (renal or peritoneal) or has a history of kidney transplant.
Has a history of myasthenia gravis or other neurological condition where gentamicin use is contraindicated as determined by the Investigator.
Has a history of epilepsy
Has a history of tendon disorders related to fluoroquinolone administration

Sites / Locations

Karr Foot Kare PA

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm Description

Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing

Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing

Outcomes

Primary Outcome Measures

Number of Participants With a Clinical Cure at Visit 3 (Day 7)

Number of participants with a clinical cure in each treatment group at Visit 3 (Day 7). Clinical Cure is defined as positive clinical response and with pathogen eradication.

Secondary Outcome Measures

Number of Participants With a Positive Clinical Response at Each Time Point

Number of patients with positive clinical response, defined as those with a clinical outcome of "clinical cure" or "clinical improvement" in each treatment group at/by each time point

Number of Participants With a Clinical Cure at Each Visit Except Visit 3 (Day 7)

clinical cure is defined as having a positive clinical response and with pathogen eradication

Number of Participants With Pathogen Eradication by Visit

Change From Baseline in Total Wound Surface Area Measured in cm^2

Wound Surface Area was measured in cm² Actual Values Total wound surface area was compared across treatments using 2-sample t-tests. Wound tracings were obtained at study visits by trained study personnel who were blinded to the patient data and regimen. A centralized imaging facility provided both wound perimeter and area measurements.

Time to Clinical Cure

clinical cure is defined as having a positive clinical response and with pathogen eradication

Visual Analog Scale (VAS) for Pain Assessment

Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is "0" and the maximum score is 100* the number of hours in that period.

Lipsky Wound Score

The Lipsky wound scoring scale consists of scoring categories for purulent drainage, non-purulent drainage, erythema, induration, tenderness, pain, local warmth and wound measurements. This wound scoring system allows us to take the size and depth of the wound into consideration as well as all signs and symptoms of inflammation and infection. A quantitative score that assess wounds both at baseline and during therapy to compare wound scores over time. The higher the score the worse the inflammation and/or infection is. The Lowest score possible is "3" and the highest score possible is "64".

Full Information

NCT ID

NCT00659646

First Posted

April 11, 2008

Last Updated

January 25, 2022

Sponsor

Innocoll

Collaborators

Premier Research Group plc

1. Study Identification

Unique Protocol Identification Number

NCT00659646

Brief Title

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

Official Title

A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers

Study Type

Interventional

2. Study Status

Record Verification Date

January 2022

Overall Recruitment Status

Completed

Study Start Date

April 2008 (undefined)

Primary Completion Date

May 2009 (Actual)

Study Completion Date

February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Innocoll

Collaborators

Premier Research Group plc

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this study is to determine whether the gentamicin-collagen sponge when combined with standard daily wound care and an oral antibiotic (levofloxacin) is safe and effective in treating moderately infected skin ulcers compared to treatment only with standard daily wound care and an oral antibiotic (levofloxacin).

Detailed Description

Infected skin ulcers with diabetes can be very debilitating because they are difficult to heal. Diabetic ulcers are responsible for frequent health care visits, and are a major predictor of amputation. Diabetic ulcers can be caused by a patient's inability to sense pain or warmth as well as peripheral vascular disease, which causes diminished blood flow to the foot. Early aggressive treatment is necessary to treat infection and ultimately prevent the need for amputation. Gentamicin is an antibiotic that is effective in treating certain kinds of infection. Collagen is a protein that is found in all mammals. The gentamicin-collagen sponge is a thin flat sponge made out of collagen that comes from cow tendons and containing gentamicin. When applied to an open ulcer, the collagen breaks down and the gentamicin is released into the ulcer, but very little is absorbed into the blood stream. The high levels of gentamicin in the open infected ulcer may help treat the infection. In this study, all subjects will be given the necessary supplies and taught how to take care their foot ulcer. All subjects will also receive oral an antibiotic (levofloxacin). Additionally, subjects who are randomly assigned to receive the gentamicin-collagen sponge will place a gentamicin-collagen sponge on their ulcer during daily wound care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Diabetic Foot Ulcer

Keywords

Diabetes, ulcers, ulcerations, infection

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

56 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm Type

Experimental

Arm Description

Arm Title

Arm Type

Active Comparator

Arm Description

Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing

Intervention Type

Drug

Intervention Name(s)

gentamicin-collagen sponge and levofloxacin

Other Intervention Name(s)

Collatamp G

Intervention Description

Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.

Intervention Type

Drug

Intervention Name(s)

Levofloxacin only

Other Intervention Name(s)

Tavanic, Levaquin

Intervention Description

levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours

Primary Outcome Measure Information:

Title

Number of Participants With a Clinical Cure at Visit 3 (Day 7)

Description

Number of participants with a clinical cure in each treatment group at Visit 3 (Day 7). Clinical Cure is defined as positive clinical response and with pathogen eradication.

Time Frame

Day 7 of treatment

Secondary Outcome Measure Information:

Title

Number of Participants With a Positive Clinical Response at Each Time Point

Description

Number of patients with positive clinical response, defined as those with a clinical outcome of "clinical cure" or "clinical improvement" in each treatment group at/by each time point

Time Frame

Day 3, 7, 10,14, 21, 28 and 42

Title

Number of Participants With a Clinical Cure at Each Visit Except Visit 3 (Day 7)

Description

clinical cure is defined as having a positive clinical response and with pathogen eradication

Time Frame

Day 3, 10, 14, 21, 28 & 42

Title

Number of Participants With Pathogen Eradication by Visit

Time Frame

Day 3, 7, 10, 14, 21 & 28

Title

Change From Baseline in Total Wound Surface Area Measured in cm^2

Description

Time Frame

Day 3, 7, 10, 14, 21, 28 & 42

Title

Time to Clinical Cure

Description

clinical cure is defined as having a positive clinical response and with pathogen eradication

Time Frame

Days 1 through 49

Title

Visual Analog Scale (VAS) for Pain Assessment

Description

Time Frame

Day 3, 7, 10, 14, 21, 28 & 42

Title

Lipsky Wound Score

Description

Time Frame

Days 3, 7, 10, 14, 21, 28, 42

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Is a man or woman aged ≥ 18 and ≤ 80 years. Has diabetes mellitus, according to the American Diabetes Association criteria. Has a single infected skin ulcer below the knee, defined as "moderate" by the Infectious Disease Society of America (IDSA) Guidelines for whom, in the Investigator's opinion, intravenous (IV) or oral antimicrobial therapy is appropriate Has had an x ray of the infected area within the 2 days immediately preceding or at Visit 1 (Baseline/Randomization) to document the presence or absence of osteomyelitis. Patients with osteomyelitis must receive appropriate surgical intervention to remove all necrotic and infected bone and otherwise meet enrollment criteria before being enrolled in the study. Meets certain minimal laboratory criteria Has an ankle brachial index (ABI) > or = 0.7 and ≤ 1.3. (Note: Patients with ABI < 0.7 or > 1.3 may be included if they have either a transcutaneous oxygen pressure or a toe pressure > or = 40 mm Hg on limb with ulcer.) If female, is nonpregnant (negative pregnancy test results at the Baseline/Randomization Visit) and nonlactating. If female, is either not of childbearing potential (defined as postmenopausal for ≥ 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing a medically acceptable methods of birth control and agrees to continue with the regimen throughout the study Willing to return to the study facility for the Final Study Visit. Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study. Exclusion Criteria: Has a known history of hypersensitivity to gentamicin (or other systemic aminoglycosides) or levofloxacin or drugs in the same class, or any of the test article or reference product components. Has a known hypersensitivity to bovine collagen. Has any uncontrolled illnesses that, in the opinion of the Investigator, would interfere with interpreting the results of the study. Has a target ulcer with a wound size > 10 × 10 cm. Has gangrenous tissue of the affected limb that cannot be removed with a single debridement. Has wound known to contain isolates resistant to levofloxacin. Has a wound associated with prosthetic material or device. Received any topical or systemic antimicrobial therapy within the 2 weeks prior to study entry (Visit 1 [Day 1]). If severely immunocompromised, may be excluded at the discretion of the Investigator. Has a history of alcohol or substance abuse in the past 12 months. Has serum creatinine > 3 mg/dL, is undergoing dialysis (renal or peritoneal) or has a history of kidney transplant. Has a history of myasthenia gravis or other neurological condition where gentamicin use is contraindicated as determined by the Investigator. Has a history of epilepsy Has a history of tendon disorders related to fluoroquinolone administration

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

David Prior

Organizational Affiliation

Innocoll

Official's Role

Study Director

Facility Information:

Facility Name

Karr Foot Kare PA

City

Lakeland

State/Province

Florida

ZIP/Postal Code

33813

Country

United States

12. IPD Sharing Statement

Citations:

PubMed Identifier

22659765

Citation

Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc. 2012 May-Jun;102(3):223-32. doi: 10.7547/1020223. Erratum In: J Am Podiatr Med Assoc. 2012 Jul-Aug;102(4):323.

Results Reference

result

Learn more about this trial

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

We'll reach out to this number within 24 hrs